- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT02381561
Ropidoxuridina nel trattamento di pazienti con carcinoma gastrointestinale avanzato sottoposti a radioterapia
Studio di fase I e farmacologia del 5-iodo-2-pirimidinone-2'-deossiribosio orale (IPdR) come profarmaco per la radiosensibilizzazione tumorale mediata da IUdR nei tumori gastrointestinali
This phase I trial studies the side effects and best dose of ropidoxuridine in treating patients with gastrointestinal cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment undergoing radiation therapy. Ropidoxuridine may help radiation therapy work better by making tumor cells more sensitive to the radiation therapy.
Panoramica dello studio
Stato
Condizioni
- Cancro al pancreas in stadio III AJCC v6 e v7
- Cancro al pancreas in stadio IV AJCC v6 e v7
- Cancro esofageo in stadio IV AJCC v7
- Cancro gastrico in stadio IV AJCC v7
- Cancro al fegato in stadio III
- Cancro al fegato in stadio IV
- Cancro al colon in stadio III AJCC v7
- Cancro del retto in stadio III AJCC v7
- Cancro al colon in stadio IIIA AJCC v7
- Cancro del retto in stadio IIIA AJCC v7
- Cancro al colon in stadio IIIB AJCC v7
- Cancro del retto in stadio IIIB AJCC v7
- Cancro al colon in stadio IIIC AJCC v7
- Cancro del retto in stadio IIIC AJCC v7
- Cancro al colon in stadio IV AJCC v7
- Cancro del retto in stadio IV AJCC v7
- Cancro al colon in stadio IVA AJCC v7
- Cancro del retto in stadio IVA AJCC v7
- Cancro al colon in stadio IVB AJCC v7
- Cancro del retto in stadio IVB AJCC v7
- Cancro al pancreas in stadio II AJCC v6 e v7
- Cancro al pancreas in stadio IIA AJCC v6 e v7
- Cancro al pancreas in stadio IIB AJCC v6 e v7
- Cancro gastrico in stadio III AJCC v7
- Cancro gastrico in stadio IIIA AJCC v7
- Cancro gastrico in stadio IIIB AJCC v7
- Cancro gastrico in stadio IIIC AJCC v7
- Carcinoma avanzato del dotto biliare
- Cancro esofageo in stadio II AJCC v7
- Stadio IIA Cancro esofageo AJCC v7
- Cancro esofageo in stadio IIB AJCC v7
- Cancro esofageo in stadio III AJCC v7
- Cancro dell'intestino tenue in stadio III AJCC v7
- Stadio IIIA Cancro esofageo AJCC v7
- Stadio IIIA Cancro dell'intestino tenue AJCC v7
- Cancro esofageo in stadio IIIB AJCC v7
- Stadio IIIB Cancro dell'intestino tenue AJCC v7
- Cancro esofageo in stadio IIIC AJCC v7
- Stadio IV del cancro dell'intestino tenue AJCC v7
- Cancro al fegato in stadio IVA
- Cancro al fegato in stadio IVB
Descrizione dettagliata
PRIMARY OBJECTIVES:
I. To conduct a phase I dose escalation trial, to determine the safety and the maximum tolerated dose (MTD), of oral (po) IPdR (ropidoxuridine) given daily for 28 consecutive days with concurrent intensity-modulated radiation therapy (IMRT) in patients with advanced gastrointestinal cancers treated with palliative radiation.
SECONDARY OBJECTIVES:
I. To observe and record anti-tumor activity. II. To establish the pharmacokinetics of daily po dosing of IPdR x 28 days. III. To assess, for patients treated at the MTD, for biochemical evidence of IPdR effect in normal tissue (circulating granulocytes) and tumor tissue (in patients with accessible tumor tissue) by measuring %iododeoxyuridine (IUdR)-deoxyribonucleic acid (DNA) cellular incorporation by flow cytometry and high-pressure liquid chromatography (HPLC) analyses.
IV. To assess the use of %IUdR-DNA cellular incorporation (measured by the investigational laboratory assays of flow cytometry and HPLC) as an exploratory biomarker of IPdR for the following effects: the %IUdR-DNA tumor cell incorporation from day 8 tumor biopsies in gastrointestinal (GI) cancer patients receiving MTD doses of IPdR as an exploratory biomarker of tumor radiosensitization using Response Evaluation Criteria in Solid Tumors (RECIST) criteria.
V. To assess the use of %IUdR-DNA cellular incorporation (measured by the investigational laboratory assays of flow cytometry and HPLC) as an exploratory biomarker of IPdR for the following effects: the %IUdR-DNA cellular incorporation in patients' circulating granulocytes taken weekly during the 28-day IPdR MTD dose, on day 29, and week 8 as an exploratory biomarker of IPdR systemic toxicities to bone marrow as measured by complete blood count (CBC)/differential values.
OUTLINE: This is a dose-escalation study of ropidoxuridine.
Beginning 30 minutes to 2 hours before radiation therapy, patients receive ropidoxuridine PO once daily (QD) on days 1-28 in the absence of disease progression or unacceptable toxicity. Beginning on day 8, patients undergo IMRT 5 days a week for 3 weeks in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up for 4 weeks.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 1
Contatti e Sedi
Luoghi di studio
-
-
Rhode Island
-
Providence, Rhode Island, Stati Uniti, 02903
- Rhode Island Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Patients must have histologically or cytologically confirmed advanced, incurable cancers of the esophagus, liver, stomach, small bowel, pancreas, bile duct, colon or rectum and be eligible to receive chest, abdominal and/or pelvic radiation therapy (RT) for palliation; documentation of this is required in physician note; concomitant systemic therapy is not allowed during administration of palliative RT; palliative RT can be considered for advanced primary tumors or metastatic disease as above
- Patients must not have received systemic chemotherapy for at least 4 weeks, and must not have received prior radiation therapy to the tumor site being irradiated on this study
- Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)
- Life expectancy of greater than 12 weeks
- Leukocytes >= 3,000/mcL
- Absolute neutrophil count >= 1,500/mcL
- Platelets >= 100,000/mcL
- Total bilirubin within normal institutional limits
- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional upper limit of normal
- Creatinine within normal institutional limits OR creatinine clearance >= 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal
- Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; men and women treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of IPdR administration
- Ability to understand and the willingness to sign a written informed consent document
- Human immunodeficiency virus (HIV) positive (+) patients with cluster of differentiation 4 (CD4) counts >= 250 cells/mm^3 on anti-viral therapy
- Women of child-bearing potential must have a negative pregnancy test
Exclusion Criteria:
- Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier
- Patients who are receiving any other investigational agents
- Patients with known brain metastases should be excluded from this clinical trial
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to IPdR
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with IPdR
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Treatment (ropidoxuridine, IMRT)
Beginning 30 minutes to 2 hours before radiation therapy, patients receive ropidoxuridine PO QD on days 1-28 in the absence of disease progression or unacceptable toxicity. Beginning on day 8, patients undergo IMRT 5 days a week for 3 weeks in the absence of disease progression or unacceptable toxicity. |
Correlative studies Correlative studies Undergo IMRT
Altri nomi:
Given PO
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
Dose massima tollerata (MTD) definita come la dose al di sotto della quale 2 o più pazienti su 6 manifestano tossicità dose-limitante
Lasso di tempo: Fino a 28 giorni
|
Fino a 28 giorni
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
%iododeoxyuridine (IUdR)-deoxyribonucleic acid (DNA) incorporation in tumor biopsies
Lasso di tempo: Up to 2 weeks
|
Correlate %IUdR-DNA incorporation in human gastrointestinal (GI) tumor biopsies in the proposed phase I and pharmacokinetic (PK) clinical trial in GI cancer patients receiving palliative abdominal and/or pelvic radiation therapy (RT) by linear regression. |
Up to 2 weeks
|
|
Pharmacokinetic (PK) incorporation in tumor biopsies
Lasso di tempo: Days 1, 15 and 22 before drug administration, at 30, 60, 120, and 240 minutes (and 24 hours on day 1 only) following drug administration
|
Correlate %IUdR-DNA incorporation in human GI tumor biopsies in the proposed phase I and PK clinical trial in GI cancer patients receiving palliative abdominal and/or pelvic RT by linear regression. |
Days 1, 15 and 22 before drug administration, at 30, 60, 120, and 240 minutes (and 24 hours on day 1 only) following drug administration
|
|
%iododeoxyuridine (IUdR)-deoxyribonucleic acid (DNA) incorporation in peripheral (circulating) granulocytes
Lasso di tempo: Up to 4 weeks after completion of study treatment
|
Correlate %IUdR-DNA incorporation in human GI tumor biopsies in the proposed phase I and PK clinical trial in GI cancer patients receiving palliative abdominal and/or pelvic RT by linear regression. |
Up to 4 weeks after completion of study treatment
|
|
Pharmacokinetic (PK) incorporation in peripheral (circulating) granulocytes
Lasso di tempo: Days 1, 15 and 22 before drug administration, 30, 60, 120, and 240 minutes (and 24 hours on day 1 only) following drug administration
|
Correlate %IUdR-DNA incorporation in human GI tumor biopsies in the proposed phase I and PK clinical trial in GI cancer patients receiving palliative abdominal and/or pelvic RT by linear regression. |
Days 1, 15 and 22 before drug administration, 30, 60, 120, and 240 minutes (and 24 hours on day 1 only) following drug administration
|
|
Tumor response relationship to the %iododeoxyuridine (IUdR)-deoxyribonucleic acid (DNA) incorporation using Response Evaluation Criteria in Solid Tumors (RECIST) criteria based on high-pressure liquid chromatography (HPLC) and flow cytometry measurements
Lasso di tempo: Day 8
|
Tumor response is the dependent variable and can be binomial (i.e. response versus [vs.] no response) or multinomial (i.e. complete response, partial response, stable disease or progressive disease) and the %IUdR-DNA incorporation is the independent variable. |
Day 8
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Timothy J Kinsella, Rhode Island Hospital
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stimato)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Neoplasie per sede
- Neoplasie
- Malattie intestinali
- Neoplasie gastrointestinali
- Neoplasie dell'apparato digerente
- Malattie dell'apparato digerente
- Malattie gastrointestinali
- Malattie dello stomaco
- Neoplasie colorettali
- Neoplasie intestinali
- Malattie del retto
- Neoplasie della testa e del collo
- Malattie del fegato
- Malattie del colon
- Malattie esofagee
- Neoplasie allo stomaco
- Neoplasie Rettali
- Neoplasie del colon
- Neoplasie esofagee
- Neoplasie del fegato
- Terapie
- Radioterapia
- Radioterapia, conforme
- Radioterapia, assistita da computer
- Radioterapia, modulata intensità
- ropidoxuridina
Altri numeri di identificazione dello studio
- NCI-2015-00258
- NCI-2015-00258 (Identificatore di registro: CTRP (Clinical Trial Reporting Program))
- BRUOG 265
- 9882 (Altro identificatore: CTEP)
- 9882 (Altro identificatore: Rhode Island Hospital)
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .